Since the success of hGH synthesis by recombinant DNA technology (Goeddel et al., 1979) , several investigators have reported the properties and biological activities of methionyl-hGH (m-hGH) in man and animals (Olson et al., 1981 , Hizuka et al., 1982 , Rosenfeld et al., 1982a , 1982b , Frigeri et al., 1982 , Hintz et al., 1982 . We have previously reported biological effects of the first preparation of m-hGH (Somatonorm(R) I) in normal healthy volunteers (Takano et al., 1983a) and in patients with GH deficiency (Takano et al., 1983b) . In this study, we investigated the growth response and antigenicity of further purified preparations of m-hGH, Somatonorm II and III, in the treatment of patients with GH deficiency. Furthermore, we have studied the growth response and serum hGH antibody after switching Somatonorm I and II to pituitary extracted hGH in patients treated with Somatonorm I and II. This study TAKANO et al. Endocrinol. Japon. October 1986 was performed between October of 1982 and February of 1986.
Materials and Methods
Patients and study design The patients with GH deficiency consisted of 44 boys and 18 girls aged 4-16 years. The diagnosis of GH deficiency was according to the recognized criteria of this disease. Features of pituitary dwarfs used in this study: 1) Peak plasma GH level was less than 5 ng/ ml to insulin induced hypoglycemia. 2) Their birth weight was more than 2500 g . 3) Their bone age was less than 11 years in boys and less than 10 years in girls (prepubertal). 4) They had no prior history of treatment with hGH or anabolic agents. 5) In cases where they had other hormone deficiencies, they were under suitable replacement therapy. The aetiology of the GH deficiency in 52 patients was considered to be idiopathic , since all had normal lateral skull X-rays and normal CT scans. Seven patients were operated on for craniopharyngioma and one patient was operated on for cerebellar tumor at least one year before this study. Two patients had received Liniac and 6°Co irradiation a year and a half before and four years before for their pinealoma , respectively. Each patient received 0.5 IU/kg/w of three different preparations of m-hGH in two to four divided doses per week by intramuscular injection for 3-14 months. The patients treated with m-hGH were switched to pituitary extracted hGH (p-hGH) in the same dosages after experimental treatment with m-hGH.
The patients treated with Somatonorm I were those reported earlier (Takano et al., 1983b) .
During the treatment, vital signs and height and body weight were checked by the same physician. Blood count, urinalysis, routine chemistries, and measurement of antibody to hGH were performed once a month during the treatment with m-hGH. After switching from mhGH to p-hGH, the patients visited the hospital every two or three months to have the above factors rechecked. Bone age was evaluated both before and every 6 months after the treatment.
Informed consent was obtained from each subject and/or the parents, and the experimental Table 2 . Growth rate (cm/year) during m-hGH followed by p-hGH treatment according to the titer of hGH antibody observed at the end of m-hGH (Somatonorm I and II) treatment. The lower binding capacity in antibody produced by Somatonorm II, in addition to the lower titer, might explain the faster disappearance rate of this antibody compared with that of Somatonorm I. From the brief analysis of disappearance of the antibody, we observed that hGH antibody with a titer of less than 102 disappeared within 6 months, and that with a titer of 103 disappeared within one year. In spite of the formation of hGH antibody, growth rate did not decrease in 48 of 49 GH deficient children.
Only one patient treated with highly purified preparation, Somatonorm III, had growth attenuation. The titer of hGH antibody was 105-106 and its binding capacity measured by KabiVitrum AB was 2.4 mg hGH/ L.
As to the antigenicity of m-hGH, it is now felt that a minute contamination of E. coli protein may act as adjuvant to enhance immunogenicity of m-hGH. The possibility that the extra amino acid of methionine residue acts in the production of the antibody is denied at present.
The clinical trial of methionine free biosynthetic hGH, which has been carried out in Japan since December 1985, will provide further information on the antigenicity of biosynthetic hGH preparation.
